Vicky Lehmann1,2, Marrit A Tuinman3, Madelaine C Keim1, Adrien M Winning1, Randal S Olshefski4, Rajinder P S Bajwa4, Mariët Hagedoorn3, Cynthia A Gerhardt1,2. 1. Center for Biobehavioral Health, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio. 2. Department of Pediatrics, The Ohio State University, Columbus, Ohio. 3. Healthy Psychology Research Section, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 4. Hematology/Oncology & BMT, Nationwide Children's Hospital, Columbus, Ohio.
Abstract
BACKGROUND: Risk factors for impairment in psychosexual development and satisfaction among adult survivors of childhood cancer are poorly understood. The authors compared psychosexual outcomes between survivors and healthy controls, and tested whether at-risk survivors can be identified by 1) treatment neurotoxicity or 2) diagnosis. METHODS: A total of 144 young adult survivors of childhood cancer and 144 matched controls completed questionnaires regarding psychosexual development, sexual satisfaction, and satisfaction with relationship status. Survivors were aged 20 to 40 years and were 5 to 34 years after diagnosis. Using medical chart data, survivors were divided into non-neurotoxic (48 survivors), low-dose (36 survivors), and high-dose (58 survivors) neurotoxic treatment groups. RESULTS: Apart from having fewer lifetime sex partners, survivors did not appear to differ from controls. However, survivors of brain tumors and any survivor who received high-dose neurotoxic treatment reported the lowest rates of achieving milestones of psychosexual development, whereas sexual and relationship status satisfaction were found to be related to relationship status. Neurotoxic treatment intensity further distinguished between survivors of brain tumors with and without psychosexual impairment. CONCLUSIONS: The intensity of neurotoxic treatment may be a valuable indicator of risk for psychosexual impairment relative to diagnosis alone. Health care providers should assess romantic/sexual problems among survivors at risk and make referrals if needed. Cancer 2017;123:1869-1876.
BACKGROUND: Risk factors for impairment in psychosexual development and satisfaction among adult survivors of childhood cancer are poorly understood. The authors compared psychosexual outcomes between survivors and healthy controls, and tested whether at-risk survivors can be identified by 1) treatment neurotoxicity or 2) diagnosis. METHODS: A total of 144 young adult survivors of childhood cancer and 144 matched controls completed questionnaires regarding psychosexual development, sexual satisfaction, and satisfaction with relationship status. Survivors were aged 20 to 40 years and were 5 to 34 years after diagnosis. Using medical chart data, survivors were divided into non-neurotoxic (48 survivors), low-dose (36 survivors), and high-dose (58 survivors) neurotoxic treatment groups. RESULTS: Apart from having fewer lifetime sex partners, survivors did not appear to differ from controls. However, survivors of brain tumors and any survivor who received high-dose neurotoxic treatment reported the lowest rates of achieving milestones of psychosexual development, whereas sexual and relationship status satisfaction were found to be related to relationship status. Neurotoxic treatment intensity further distinguished between survivors of brain tumors with and without psychosexual impairment. CONCLUSIONS: The intensity of neurotoxic treatment may be a valuable indicator of risk for psychosexual impairment relative to diagnosis alone. Health care providers should assess romantic/sexual problems among survivors at risk and make referrals if needed. Cancer 2017;123:1869-1876.
Authors: Vicky Lehmann; Leena Nahata; Amanda C Ferrante; Jennifer A Hansen-Moore; Nicholas D Yeager; James L Klosky; Cynthia A Gerhardt Journal: J Adolesc Young Adult Oncol Date: 2018-02-21 Impact factor: 2.223
Authors: Keagan G Lipak; Joseph R Rausch; Rachel S Fisher; Kemar V Prussien; Olivia E Clark; Ansley E Kenney; Alexandra C Himelhoch; Randal S Olshefski; Leena Nahata; Kathryn Vannatta; Bruce E Compas; Cynthia A Gerhardt Journal: Qual Life Res Date: 2021-08-29 Impact factor: 3.440
Authors: Adrien M Winning; Katianne Howard Sharp; Amanda C Ferrante; Jessica Ralph; Leandra Desjardins; Debra L Friedman; Tammi K Young-Saleme; Kathryn Vannatta; Bruce E Compas; Cynthia A Gerhardt Journal: J Pediatr Psychol Date: 2022-08-12
Authors: Natasha N Frederick; Vicky Lehmann; Astrid Ahler; Kristen Carpenter; Brooke Cherven; James L Klosky; Leena Nahata; Gwendolyn P Quinn Journal: Pediatr Blood Cancer Date: 2021-12-06 Impact factor: 3.838
Authors: Alexandra C Himelhoch; Taylor M Datillo; Marrit A Tuinman; Cynthia A Gerhardt; Vicky Lehmann Journal: J Adolesc Young Adult Oncol Date: 2021-05-17 Impact factor: 2.223
Authors: Marloes Nies; Bernadette L Dekker; Esther Sulkers; Gea A Huizinga; Mariëlle S Klein Hesselink; Heleen Maurice-Stam; Martha A Grootenhuis; Adrienne H Brouwers; Johannes G M Burgerhof; Eveline W C M van Dam; Bas Havekes; Marry M van den Heuvel-Eibrink; Eleonora P M Corssmit; Leontien C M Kremer; Romana T Netea-Maier; Heleen J H van der Pal; Robin P Peeters; John T M Plukker; Cécile M Ronckers; Hanneke M van Santen; Anouk N A van der Horst-Schrivers; Wim J E Tissing; Gianni Bocca; Thera P Links Journal: Eur J Endocrinol Date: 2017-12-18 Impact factor: 6.664
Authors: Taylor M Dattilo; Randal S Olshefski; Leena Nahata; Jennifer A Hansen-Moore; Cynthia A Gerhardt; Vicky Lehmann Journal: Support Care Cancer Date: 2021-05-07 Impact factor: 3.603